

# Melanoma Committee

## Leadership

Chair: ..... Sapna P. Patel, MD  
 Vice-Chair: ..... Roger S. Lo, MD, PhD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Michael Wu, PhD  
 ..... Megan Othus, PhD  
 ..... James Moon, MS  
 ..... Hongli Li, MS

## Scientific Leadership

Translational Medicine: ..... William E. Carson, III, MD  
 Radiation Oncology: ..... Evan J. Wuthrick, MD  
 Surgery: ..... John Robert Hyngstrom, MD  
 Dermatology: ..... Clara Curiel-Lewandrowski, MD  
 Imaging: ..... Ari M. VanderWalde, MD  
 Medical Oncology: ..... Sapna Pradyuman Patel, MD  
 Pathology: ..... TBD  
 Non-Melanoma Skin Cancer: ..... Nikhil I. Khushalani, MD  
 Early Therapeutics: ..... Jeffrey A. Sosman, MD  
 SWOG's ECOG Liaisons: ..... Thach-Giao Truong, MD  
 ECOG's SWOG Liaisons: ..... David H. Lawson, MD  
 ..... Andrew Poklepovic, MD  
 Digital Engagement: ..... Zeynep Eroglu, MD

## Designates

Cancer Control Liaison: ..... Sancy Leachman, MD, PhD  
 ..... Thach-Giao Truong, MD (Survivorship)  
 Data Coordinator: ..... Matt Gospe, BS  
 ..... Michele Counts, BS  
 ..... Tonya Johnson, BS  
 Oncology Research Professionals:  
 CRA: ..... Kathryn Allen, BA, CCRP  
 Nurse: ..... Lisa S. Morgan, RN, OCN  
 Patient Advocate: ..... Samantha Guild, J.D.  
 Pharmaceutical Science: ..... Sun "Coco" Yang, PharmD, PhD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Manager: ..... Catrina De Los Santos-Mireles  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Saturday, October 14, 2023 9:30 a.m. - 11:30 a.m.  
 Room: Regency B (Ballroom Level, West Tower)

## Agenda

### Active Studies

**S2015**, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22.

**S2000**, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020.

**CTSU/EA6174**, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Temporarily Closed to Accrual as of 04/07/2023

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015.

**CTSU/EA6192**, "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020.

**A091903**, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022.

### Closed Studies

**S1801**, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

**S1512**, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

**S1607**, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

# Melanoma Committee

**S1616**, “A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

**S1404**, “A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

**CTSU/EA6134**, “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

**CTSU/EA6183**, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPH Activated: 02/18/2020. Closed: 09/23/2022.

## Studies in Development

**S2305**, “Phase II Study of the Triplet Combination of Relatlimab, Nivolumab, and Ipilimumab for Melanoma with Prior Progression on Immune Checkpoint Inhibitor Therapy” Drs. Naing and Patel

**S2412**, “Phase III Study of Neoadjuvant/Adjuvant Pembrolizumab versus Adjuvant Pembrolizumab in Resectable Melanoma” Drs. Sharon and Patel

## Melanoma Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	S1801	S2000	S2015	A091903	EA6141	EA6174	EA6192
Banner MD Anderson Cancer Center	3	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	-	-	-	3	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	1	-	-	-	-	-	-
Boston Medical Center	1	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	16	-
Cancer Research Consortium of West Michigan NCORP	26	-	43	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	1	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	2	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	7	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	3	-	-
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	-	2	-	-
Duke University - Duke Cancer Institute LAPS	-	-	2	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	1	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	1	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	6	-	-	-	-	-	-
Intermountain Medical Center	-	-	1	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	14	-	-	-	25	-	-
Loma Linda University Medical Center	2	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	5	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	5	-	-	-	-
Michigan Cancer Research Consortium NCORP	5	-	-	-	-	-	-
Moffitt Cancer Center	-	15	17	-	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	1	-	-	-	-	-	-

## Melanoma Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1801	S2000	S2015	A091903	EA6141	EA6174	EA6192
Northwell Health NCORP	7	-	-	-	-	-	-
Northwestern University LAPS	13	-	20	-	1	1	5
Ohio State University Comprehensive Cancer Center LAPS	13	1	10	-	-	3	3
Pacific Cancer Research Consortium NCORP	3	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	1	-
Sutter Cancer Research Consortium	-	-	-	-	5	1	-
The Don and Sybil Harrington Cancer Center	3	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	3	-	-	-	4	8	-
UCLA / Jonsson Comprehensive Cancer Center	6	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	1	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	8	-	-	1	-	3	-
University of Alabama at Birmingham / Deep South Research Consortium	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	3	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	2	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	8	-	17	-	-	1	-
University of Kentucky/Markey Cancer Center	4	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	15	2	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-
University of Rochester LAPS	4	-	2	-	2	1	-
University of Texas Health Science Center at San Antonio	-	-	-	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	10	-	6	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	20	-	11	-	-	8	-
Western States Cancer Research NCORP	-	-	-	-	1	-	-
Wisconsin NCI Community Oncology Research Program	9	-	3	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	9	-	6	1	-
ALLIANCE	32	1	14	-	-	-	-
ECOG-ACRIN	50	4	54	-	-	-	-
NRG	47	1	18	-	-	-	-
<b>Total</b>	<b>345</b>	<b>28</b>	<b>245</b>	<b>1</b>	<b>53</b>	<b>53</b>	<b>8</b>